Biogen Inc.: FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with

Related Keywords

Australia ,Japan ,Tokyo ,New Zealand ,United Kingdom ,Massachusetts ,United States ,China ,Cambridge ,Cambridgeshire ,Russia ,Dennis Riedl ,Haruo Naito ,Christophera Viehbacher ,Mike Hencke ,Natacha Gassenbach ,Libby Holman ,Communications Department ,Linkedin ,Twitter ,Investor Relations Department ,National Institute On ,Ministry Of Health ,Eisai Europe Ltd ,Advisory Committee ,Biogen Inc ,Nasdaq ,Facebook ,Public Relations Department ,National Institutes Of Health ,Drug Administration ,Eisai Inc ,Washington University School Of Medicine ,Exchange Commission ,Eisai Co Ltd ,Youtube ,Alzheimer Network Trials Unit ,European Medicines Agency ,National Medical Products Administration ,United Nations Sustainable Development Goals Sdgs ,Devices Agency ,Alzheimer Clinical Trial Consortium ,Confirmatory Phase ,Prescription Drug User Fee Act ,Biologics License Application ,Priority Review ,Accelerated Approval Pathway ,Clinical Trials ,New England Journal ,Dose Management ,Carrier Status ,Antithrombotic Medication ,Medical Devices Agency ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Corporate Concept ,United Nations Sustainable Development Goals ,Private Securities Litigation Reform Act ,Different Forms ,Amyloid Beta Might Explain Efficacy ,Side Effects ,Accessed February ,Biogen ,Oaccepts ,Disai ,Filing ,Supplemental ,Iologics ,License ,Application ,Migrants ,Priority ,Review ,Traditional ,Approval ,Leqembi ,Lecanemab ,Trmb ,Treatment ,Lzheimer ,Disease ,